In pancreatic cancer, inhibition of mitochondrial uncoupling protein 2 (UCP2) by genipin enhances the efficacy of 2-deoxyglucose (2-DG), suggesting that co-targeting the UCP2–PKM2 metabolic axis disrupts mitochondrial bioenergetics and glycolysis simultaneously (104). This evidence concerns the gene PKM and pancreatic neoplasm.